Genus PLC
12 November 2007
12 November 2007
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, JAPAN, CANADA, AUSTRALIA OR THE
REPUBLIC OF IRELAND
Genus plc
('Genus' or 'the Company')
Commencement of trading on the Official List
Genus plc, a world leading animal genetics company, is pleased to announce that
admission to the Official List of the UK Listing Authority and the London Stock
Exchange's main market for listed securities of 59,204,190 ordinary shares of 10
pence ('Ordinary Shares') has occurred ('Admission') and that trading in its
Ordinary Shares became effective from 8.00 am today. The Company's FTSE
classification is Biotechnology.
Copies of the prospectus dated 6 November 2007, published in connection with
Admission are available from the 'Investors' section of the Company's website at
www.genusplc.com. The prospectus has also been submitted to the UKLA's Document
Viewing Facility situated at: Financial Services Authority, 25 The North
Colonnade, Canary Wharf, London, E14 5HS.
Enquiries:
Genus plc Tel: 01256 345970
Richard Wood, Chief Executive
Martin Boden, Finance Director
Landsbanki Securities (UK) Limited Tel: 020 7426 9000
Sponsor & Joint Broker
Shaun Dobson
Buchanan Communications Tel: 020 7466 5000
Charles Ryland / Suzanne Brocks
About Genus
Genus creates and sells added value products for livestock farming and food
producers by creating advances to animal breeding through biotechnology. Its
non-Genetically Modified Organism (GMO) technology is applicable across all
livestock species but is only commercialised by Genus in the bovine and porcine
farming sectors.
Genus' worldwide sales are made in seventy countries under the trade marks 'ABS'
(dairy and beef cattle) and 'PIC' (pigs) and comprise semen and breeding animals
with superior genetics to those animals currently in production. Customers
produce offspring with greater production efficiency, milk and meat output and
quality and use these to supply the global dairy and meat supply chain.
Genus' competitive edge has been created from the ownership and control of
proprietary lines of breeding animals, the biotechnology used to improve them
and the Group's global production and distribution network.
Headquartered in Basingstoke, England, Genus companies operate in 30 countries
on five continents, with research laboratories located in Madison, USA.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.